Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 37
2021 40
2022 27
2023 4
2024 13
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

105 results

Results by year

Filters applied: . Clear all
Page 1
A combined proteomic and metabolomic analysis of the early aborted embryonic tissues with maternal COVID-19 infection.
Ling L, Xu G, Fang M, Chen J, Gong M, Wang T, Ju R, Nie S. Ling L, et al. J Proteomics. 2025 Jan 8:105383. doi: 10.1016/j.jprot.2025.105383. Online ahead of print. J Proteomics. 2025. PMID: 39793701
Our findings provide a network of protein regulation and metabolite perturbation during early embryonic development with COVID-19 infection. Our findings can provide valuable insights for further exploration of the complex mechanism of COVID-19-associa …
Our findings provide a network of protein regulation and metabolite perturbation during early embryonic development with COVID-19 …
X-206 exhibits broad-spectrum anti-beta-coronavirus activity, covering SARS-CoV-2 variants and drug-resistant isolates.
Sasaki J, Sato A, Sasaki M, Okabe I, Kodama K, Otsuguro S, Yasuda K, Kojima H, Orba Y, Sawa H, Maenaka K, Yanagi Y, Hashiguchi T. Sasaki J, et al. Antiviral Res. 2024 Dec;232:106039. doi: 10.1016/j.antiviral.2024.106039. Epub 2024 Nov 19. Antiviral Res. 2024. PMID: 39571911
Notably, several antiviral drugs against SARS-CoV-2, such as nirmatrelvir and remdesivir, have been approved. However, no approved vaccines or antiviral agents are available for other highly pathogenic beta-coronaviruses. ...X-206 exhibited antiviral a …
Notably, several antiviral drugs against SARS-CoV-2, such as nirmatrelvir and remdesivir, have been approved. However, …
Mutation of a highly conserved isoleucine residue in loop 2 of several beta-coronavirus macrodomains indicates that enhanced ADP-ribose binding is detrimental for replication.
Kerr CM, Pfannenstiel JJ, Alhammad YM, O'Connor JJ, Ghimire R, Shrestha R, Khattabi R, Saenjamsai P, Parthasarathy S, McDonald PR, Gao P, Johnson DK, More S, Roy A, Channappanavar R, Fehr AR. Kerr CM, et al. J Virol. 2024 Nov 19;98(11):e0131324. doi: 10.1128/jvi.01313-24. Epub 2024 Oct 10. J Virol. 2024. PMID: 39387584 Free article.
To determine how the biochemical activities of these residues impact CoV replication, the isoleucine and the phenylalanine residues were mutated to alanine (I-A/F-A) in both recombinant Mac1 proteins and recombinant CoVs, including murine hepatitis virus, Middle East respi …
To determine how the biochemical activities of these residues impact CoV replication, the isoleucine and the phenylalanine residues were mut …
Cytokines and Other Laboratory Parameters of Hospitalized COVID-19 Patients that Predict Intensive Care Unit Admission.
Cakir N, Gozke E, Ekinci SC, Isik SA, Osken S, Kaya Z, Guner EA, Ak F, Yazicilar HA, Kilic H, Anil BS, Ozgul M. Cakir N, et al. Clin Lab. 2024 Oct 1;70(10). doi: 10.7754/Clin.Lab.2024.240109. Clin Lab. 2024. PMID: 39382921
RESULTS: COVID-19 was confirmed by PCR in 116 hospitalized patients. The mean age was 55.3 16.4 years. ...CONCLUSIONS: High NLR and LDH and low Alb levels, especially with an increase in MCP-1 and IL-6, were found to be the best predictors of a serious COVID- …
RESULTS: COVID-19 was confirmed by PCR in 116 hospitalized patients. The mean age was 55.3 16.4 years. ...CONCLUSIONS: High NL …
Pharmacological targets and validation of remdesivir for the treatment of COVID-19-associated pulmonary fibrosis: A network-based pharmacology and bioinformatics study.
Zhao X, Yang L. Zhao X, et al. Medicine (Baltimore). 2024 Sep 27;103(39):e39062. doi: 10.1097/MD.0000000000039062. Medicine (Baltimore). 2024. PMID: 39331891 Free PMC article.
The objective of this study was to employ bioinformatics and network pharmacology methodologies to investigate the targets and molecular mechanisms of remdesivir in the treatment of coronavirus disease 2019 (COVID-19)-associated pulmonary fibrosis (PF). Several open …
The objective of this study was to employ bioinformatics and network pharmacology methodologies to investigate the targets and molecular mec …
The triple combination of Remdesivir (GS-441524), Molnupiravir and Ribavirin is highly efficient in inhibiting coronavirus replication in human nasal airway epithelial cell cultures and in a hamster infection model.
Do TND, Abdelnabi R, Boda B, Constant S, Neyts J, Jochmans D. Do TND, et al. Antiviral Res. 2024 Nov;231:105994. doi: 10.1016/j.antiviral.2024.105994. Epub 2024 Sep 3. Antiviral Res. 2024. PMID: 39237005 Free PMC article.
The use of fixed dose-combinations of antivirals with different mechanisms of action has proven key in the successful treatment of infections with HIV and HCV. For the treatment of infections with SARS-CoV-2 and possible future epi-/pandemic coronaviruses, it …
The use of fixed dose-combinations of antivirals with different mechanisms of action has proven key in the successful treatment of infection …
An in vitro study for reducing the cytotoxicity and dose dumping risk of remdesivir via entrapment in nanostructured lipid carriers.
Amiri F, Ziaei Chamgordani S, Ghourchian H. Amiri F, et al. Sci Rep. 2024 Aug 21;14(1):19360. doi: 10.1038/s41598-024-70003-7. Sci Rep. 2024. PMID: 39169059 Free PMC article.
The aim of this study was to synthesize and evaluate nanostructured lipid carriers (NLCs) loaded with Remdesivir (RDV) to control its side effects in COVID-19 patients. Due to the low solubility and short half-life of RDV in the blood, an injectable formulation was …
The aim of this study was to synthesize and evaluate nanostructured lipid carriers (NLCs) loaded with Remdesivir (RDV) to control its side e …
Efficacy and Safety of Remdesivir in People With Impaired Kidney Function Hospitalized for COVID-19 Pneumonia: A Randomized Clinical Trial.
Sise ME, Santos JR, Goldman JD, Tuttle KR, Teixeira JP, Seibert AF, Koullias Y, Llewellyn J, Regan S, Zhao Y, Huang H, Hyland RH, Osinusi A, Winter H, Humeniuk R, Hulter HN, Gottlieb RL, Fusco DN, Birne R, Stancampiano FF, Libertin CR, Small CB, Plate M, McPhail MJ; REDPINE Investigators. Sise ME, et al. Clin Infect Dis. 2024 Nov 22;79(5):1172-1181. doi: 10.1093/cid/ciae333. Clin Infect Dis. 2024. PMID: 38913574 Free PMC article. Clinical Trial.
BACKGROUND: Few antiviral therapies have been studied in patients with coronavirus disease 2019 (COVID-19) and kidney impairment. Herein, the efficacy, safety, and pharmacokinetics of remdesivir, its metabolites, and sulfobutylether-beta-cyclodextrin excipien …
BACKGROUND: Few antiviral therapies have been studied in patients with coronavirus disease 2019 (COVID-19) and kidney impairme …
Cyclic beta(2,3)-amino acids improve the serum stability of macrocyclic peptide inhibitors targeting the SARS-CoV-2 main protease.
Miura T, Malla TR, Brewitz L, Tumber A, Salah E, Lee KJ, Terasaka N, Owen CD, Strain-Damerell C, Lukacik P, Walsh MA, Kawamura A, Schofield CJ, Katoh T, Suga H. Miura T, et al. Bull Chem Soc Jpn. 2024 Mar 6;97(5):uoae018. doi: 10.1093/bulcsj/uoae018. eCollection 2024 May. Bull Chem Soc Jpn. 2024. PMID: 38828441 Free PMC article.
Here we report on the design and application of a macrocyclic peptide library incorporating 3 kinds of cbetaAAs: (1R,2S)-2-aminocyclopentane carboxylic acid (beta(1)), (1S,2S)-2-aminocyclohexane carboxylic acid (beta(2)), and (1R,2R)-2-aminocyclopentane carboxylic a …
Here we report on the design and application of a macrocyclic peptide library incorporating 3 kinds of cbetaAAs: (1R,2S)-2-aminocyclopentane …
Evaluating treatment efficacy in hospitalized COVID-19 patients, with applications to Adaptive COVID-19 Treatment Trials.
Lin DY, Wang J, Gu Y, Zeng D. Lin DY, et al. Clin Trials. 2024 Aug;21(4):500-506. doi: 10.1177/17407745241238443. Epub 2024 Apr 15. Clin Trials. 2024. PMID: 38618926 Free PMC article.
BACKGROUND: The current endpoints for therapeutic trials of hospitalized COVID-19 patients capture only part of the clinical course of a patient and have limited statistical power and robustness. ...CONCLUSIONS: The proposed methods comprehensively characterize the …
BACKGROUND: The current endpoints for therapeutic trials of hospitalized COVID-19 patients capture only part of the clinical c …
105 results